Menu

Long-term outcome with interstitial brachytherapy boost in the treatment of women with early-stage breast cancer

R. NEUMANOVA, J. PETERA, T. FRGALA, L. DUSEK, J. JARKOVSKY, R. KURICKA

Abstract:

Breast conserving surgery followed by adjuvant radiotherapy and eventually by systemic treatment represent the current trend in therapy of the early-stage breast carcinoma. Local control and the final cosmetic effect are important factors in breast conserving therapeutic approaches. We evaluated 215 patients who underwent breast conserving surgery (BCS) followed by adjuvant radiotherapy (RT) in our institute between October 1996 and February 2004. External beam radiotherapy (EBRT) was performed using a Cobalt- 60 or linear accelerator (LINAC), the boost was administered via high dose rate interstitial brachytherapy (HDR BRT) employing the Gammamed afterloading system. Patient survival was evaluated using the Kaplan-Meier method (disease-free survival – DFS, overall survival – OS). Late radiotherapy effects were evaluated using the LENT scales. The cosmetic effect (CE) was rated on a 4-grade scale by the patient and a committee; the Breast Retraction Assessment (BRA) was used to objectively assess the extent of the breast deformation and areolar deviation. The median follow-up in our group of patients was 70 months (from 20 to 136 months). Local control of the disease after 5 years was achieved in 98.5% of the patients, DFS was 88.7%, the distant disease-free survival (DDFS) was 89.9% and the overall 5-year survival was 91,8%. Medium vs. heavy fibrosis were recorded in 31.2% vs. 4.2% of the patients, medium vs. heavy teleangiectasia in 11.2% vs. 14.0% of the patients, and medium vs. heavy pigmentations in 6.5% vs. 3.3% of the patients, respectively. In all other cases none or minimal late radiotherapy effects occurred. The total CE was significantly influenced by the extent of the surgery (smaller deformations following tumorectomy

Issue: 1/2007

Volume: 2007

Pages: 413 — 423

Shopping cart is empty